CN116209441A - 新型胺衍生物 - Google Patents

新型胺衍生物 Download PDF

Info

Publication number
CN116209441A
CN116209441A CN202180063922.5A CN202180063922A CN116209441A CN 116209441 A CN116209441 A CN 116209441A CN 202180063922 A CN202180063922 A CN 202180063922A CN 116209441 A CN116209441 A CN 116209441A
Authority
CN
China
Prior art keywords
benzothiazol
dihydrofuro
optionally substituted
compound
imidazol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180063922.5A
Other languages
English (en)
Chinese (zh)
Inventor
东城慎吾
浦边大辅
渡边仁
川畑亘
森山英树
朝光优子
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Carna Biosciences Inc
Original Assignee
Sumitomo Pharmaceuticals Co Ltd
Carna Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sumitomo Pharmaceuticals Co Ltd, Carna Biosciences Inc filed Critical Sumitomo Pharmaceuticals Co Ltd
Publication of CN116209441A publication Critical patent/CN116209441A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN202180063922.5A 2020-09-18 2021-09-17 新型胺衍生物 Pending CN116209441A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JP2020-157398 2020-09-18
JP2020157398 2020-09-18
JP2021122893 2021-07-28
JP2021-122893 2021-07-28
PCT/JP2021/034327 WO2022059779A1 (ja) 2020-09-18 2021-09-17 アミン誘導体

Publications (1)

Publication Number Publication Date
CN116209441A true CN116209441A (zh) 2023-06-02

Family

ID=80776131

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180063922.5A Pending CN116209441A (zh) 2020-09-18 2021-09-17 新型胺衍生物

Country Status (10)

Country Link
US (1) US20230365589A1 (https=)
EP (1) EP4215534A4 (https=)
JP (2) JP7706775B2 (https=)
KR (1) KR20230069162A (https=)
CN (1) CN116209441A (https=)
AU (1) AU2021343770A1 (https=)
BR (1) BR112023003807A2 (https=)
CA (1) CA3191617A1 (https=)
MX (1) MX2023003245A (https=)
WO (1) WO2022059779A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023008470A1 (ja) * 2021-07-28 2023-02-02 住友ファーマ株式会社 縮環アミン誘導体
WO2025170029A1 (ja) * 2024-02-09 2025-08-14 カルナバイオサイエンス株式会社 ジヒドロキナゾリノン誘導体

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1422262A (zh) * 2000-02-07 2003-06-04 艾博特股份有限两合公司 2－苯并噻唑基脲衍生物及其作为蛋白激酶抑制剂的应用
US20080045578A1 (en) * 2006-08-15 2008-02-21 Wyeth Tricyclic oxazolidone derivatives useful as PR modulators
CN102712601A (zh) * 2009-11-12 2012-10-03 赛尔维他股份公司 化合物、其制备方法、药物组合物、化合物的用途、用于调节或调控丝氨酸/苏氨酸激酶的方法以及丝氨酸/苏氨酸激酶调节剂
CN103797002A (zh) * 2011-08-19 2014-05-14 迪亚克森海特公司 Dyrk1抑制剂及其用途
US20170007583A1 (en) * 2014-02-04 2017-01-12 Lytix Biopharma As Neurodegenerative Therapies

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1679308B1 (en) 2003-10-15 2013-07-24 Ube Industries, Ltd. Novel indazole derivative
JP2010163361A (ja) 2007-04-27 2010-07-29 Dainippon Sumitomo Pharma Co Ltd キノリン誘導体
KR20100010894A (ko) 2008-07-23 2010-02-02 가부시키가이샤 키노파마 Ｄｙｒｋ를 저해하는 화합물을 함유하는 의약 조성물
US8470835B2 (en) 2009-01-13 2013-06-25 Glaxo Group Limited Pyrimidinecarboxamide derivatives as inhibitors of Syk kinase
TW201039825A (en) 2009-02-20 2010-11-16 Astrazeneca Ab Cyclopropyl amide derivatives 983
CA2816219C (en) 2010-11-01 2019-10-29 Portola Pharmaceuticals, Inc. Nicotinamides as syk modulators
UY34200A (es) 2011-07-21 2013-02-28 Bayer Ip Gmbh 3-(fluorovinil)pirazoles y su uso
WO2013043002A1 (en) 2011-09-23 2013-03-28 Yuhan Corporation Imide-containing benzothiazole derivative or its salt and pharmaceutical composition comprising the same
KR101916443B1 (ko) 2012-07-26 2018-11-08 글락소 그룹 리미티드 Pad4 억제제로서의 2-(아자인돌-2-일) 벤즈이미다졸
RS63405B1 (sr) 2013-10-25 2022-08-31 Blueprint Medicines Corp Inhibitori receptora faktora rasta fibroblasta
JP2015107945A (ja) 2013-12-05 2015-06-11 国立大学法人京都大学 神経新生に関する化合物及び医薬組成物
JP2017516850A (ja) 2014-05-23 2017-06-22 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Ｊａｋ阻害剤である５−クロロ−２−ジフルオロメトキシフェニルピラゾロピリミジン化合物
WO2016044641A2 (en) 2014-09-17 2016-03-24 Epizyme, Inc. Carm1 inhibitors and uses thereof
GB201617339D0 (en) 2016-10-12 2016-11-23 Lytix Biopharma As Therapeutic compounds
CN109206537B (zh) 2018-10-10 2021-04-09 华熙生物科技股份有限公司 一种乙酰化透明质酸钠的制备方法及其应用
US20230138851A1 (en) * 2020-01-30 2023-05-04 Carna Biosciences, Inc. Novel alkyne derivatives

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1422262A (zh) * 2000-02-07 2003-06-04 艾博特股份有限两合公司 2－苯并噻唑基脲衍生物及其作为蛋白激酶抑制剂的应用
US20080045578A1 (en) * 2006-08-15 2008-02-21 Wyeth Tricyclic oxazolidone derivatives useful as PR modulators
CN102712601A (zh) * 2009-11-12 2012-10-03 赛尔维他股份公司 化合物、其制备方法、药物组合物、化合物的用途、用于调节或调控丝氨酸/苏氨酸激酶的方法以及丝氨酸/苏氨酸激酶调节剂
CN103797002A (zh) * 2011-08-19 2014-05-14 迪亚克森海特公司 Dyrk1抑制剂及其用途
US20170007583A1 (en) * 2014-02-04 2017-01-12 Lytix Biopharma As Neurodegenerative Therapies

Also Published As

Publication number Publication date
AU2021343770A9 (en) 2024-09-12
KR20230069162A (ko) 2023-05-18
MX2023003245A (es) 2023-04-11
JP2025134941A (ja) 2025-09-17
JP7706775B2 (ja) 2025-07-14
EP4215534A1 (en) 2023-07-26
US20230365589A1 (en) 2023-11-16
EP4215534A4 (en) 2024-10-02
BR112023003807A2 (pt) 2023-03-28
CA3191617A1 (en) 2022-03-24
JPWO2022059779A1 (https=) 2022-03-24
TW202227459A (zh) 2022-07-16
AU2021343770A1 (en) 2023-05-18
WO2022059779A1 (ja) 2022-03-24

Similar Documents

Publication Publication Date Title
US10442776B2 (en) 3-alkyl-4-amido-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors
JP7819233B2 (ja) 三環式誘導体を含む阻害剤、その製造方法、及び使用
US11198699B2 (en) Compounds targeting PRMT5
KR101982912B1 (ko) 융합된 헤테로사이클릭 화합물, 이의 제조 방법, 약학적 조성물, 및 그 용도
ES2459047T3 (es) Derivados de imidazopiridin-2-ona
RU2622104C2 (ru) Макроциклические ингибиторы киназы lrrk2
EP0656360B1 (en) Trifluoromethylpyrroloindole carboxylic ester derivative and process for producing the same
US11787803B2 (en) Tetrahydro-imidazo quinoline compositions as CBP/P300 inhibitors
JP2025134941A (ja) アミン誘導体
US9453021B2 (en) Pyrimidodiazepinone compound
KR20150129016A (ko) 마크로시클릭 lrrk2 키나제 억제제
CN113939518A (zh) 作为激酶抑制剂的稠合三环化合物
EP4559917A1 (en) Compound for recovering p53 mutation function and use thereof
US20250361241A1 (en) Hpk1 inhibitor and medical use thereof
BRPI0714722A2 (pt) tetraidrofuro[3,2-b]pirrol-3-onas como inibidores de catepsina k
WO2020001449A1 (zh) 作为IRAK4抑制剂的异噻唑并[5,4-d]嘧啶类化合物
US20230053342A1 (en) Imidazolidinone compound, preparation method therefor and use thereof
JP2023138470A (ja) アミン誘導体を含有する医薬
CA2972746C (en) Production method of thiazole derivative
TWI915421B (zh) 胺衍生物
HK40090757A (en) Amine derivative
US20220112194A1 (en) Compounds targeting prmt5
KR101387400B1 (ko) 레조사이클릭산 락톤계 화합물
US20250084098A1 (en) Fused-ring amine derivative
TW202604506A (zh) 四氫吡唑并吡啶衍生物

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
TA01 Transfer of patent application right
TA01 Transfer of patent application right

Effective date of registration: 20240708

Address after: Japan Hyogo Prefecture

Applicant after: CARNA BIOSCIENCES, Inc.

Country or region after: Japan

Address before: 6-8 Daoxiu cho 2-chome, Chuo ku, Osaka City, Osaka Prefecture, Japan

Applicant before: SUMITOMO PHARMACEUTICALS CO.,LTD.

Country or region before: Japan

Applicant before: CARNA BIOSCIENCES, Inc.